greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2025

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2025: revenue JPY 4,582 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2025 it reported revenue of JPY 4,582 billion ($30.1 billion at the year's average rate), up 7.5% on the year before. Its profit attributable to shareholders was JPY 108 billion, down 25.1%, and diluted earnings per share JPY 67.23.

Revenue
JPY 4,582 billion
+7.5% on the year
FY2018FY2025
Operating margin
7.5%
5.0% a year earlier
FY2018FY2025
Net income
JPY 108 billion
-25.1% on the year
FY2018FY2025
Diluted EPS
JPY 67.23
-26.3% on the year
FY2018FY2025

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2024Mar 2025
Revenue4,2644,582
Cost of sales1,4271,580
Research and development730730
Operating profit214343
Finance costs220210
Profit before tax52.8175
Income tax-91.466.9
Profit for the year144108
Profit attributable to shareholders144108
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2024Mar 2025
Diluted EPS91.1667.23
Basic EPS92.0968.36
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2024Mar 2025
Cash from operations7161,057
Purchase of property, plant and equipment175201
Free cash flow541856
Cash from investing-464-367
Cash from financing-354-751
Depreciation and amortisation728761
Buybacks2.351.9
Dividends paid287302
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2024Mar 2025
Funded by
Equity attributable to shareholders7,2736,935
Non-controlling interests0.70.9
Borrowings, as filed4,8444,515
Lease liabilities620573
Other liabilities2,3712,224
Total equity and liabilities15,10914,248
Owned
Property, plant and equipment1,9901,968
Goodwill5,4105,324
Other intangible assets4,2753,632
Cash and cash equivalents458385
Trade and other receivables668709
Inventories1,2101,217
Other assets1,0981,012
Total assets15,10914,248
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2024Mar 2025
Operating margin5.0%7.5%
Net margin3.4%2.4%
Free cash flow margin12.7%18.7%
Return on year-end equity2.0%1.6%
Effective tax rate-173.1%38.2%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2025, filed 17 June 2026: the filing. The figures are in yen as filed.